{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T07:18:20Z","timestamp":1794467900990,"version":"4.9.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,9]],"date-time":"2021-10-09T00:00:00Z","timestamp":1633737600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,9]],"date-time":"2021-10-09T00:00:00Z","timestamp":1633737600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001713","name":"European and Developing Countries Clinical Trials Partnership","doi-asserted-by":"publisher","award":["EDCTP"],"award-info":[{"award-number":["EDCTP"]}],"id":[{"id":"10.13039\/501100001713","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001713","name":"European and Developing Countries Clinical Trials Partnership","doi-asserted-by":"publisher","award":["TMA2017CDF-1878-PRIMAQUINE Roll out"],"award-info":[{"award-number":["TMA2017CDF-1878-PRIMAQUINE Roll out"]}],"id":[{"id":"10.13039\/501100001713","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Primaquine is a gametocytocidal drug recommended by the World Health Organization (WHO) in a single-low dose combined with artemisinin-based combination therapy (ACT) for the treatment and prevention of<jats:italic>Plasmodium falciparum<\/jats:italic>malaria transmission. Safety monitoring concerns and the lack of a universal validated and approved primaquine pharmacovigilance tool is a challenge for a national rollout in many countries. This study aimed to explore the acceptance, reliability and perceived effectiveness of the primaquine roll out monitoring pharmacovigilance tool (PROMPT).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This study was conducted in three dispensaries in the Coastal region of Eastern Tanzania. The study held six in-depth interviews with healthcare providers and six participatory focus group discussions with malaria patients (3) and parents\/guardians of sick children (3). Participants were purposively sampled. Thematic analysis was conducted with the aid of NVivo qualitative analysis software.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The respondents\u2019 general acceptance and perceived effectiveness of the single-low dose primaquine and PROMPT was good. Screening procedure for treatment eligibility and explaining to patients about the possible adverse events was considered very useful for safety reasons. Crushing and dissolving of primaquine tablet to get the appropriate dose, particularly in children, was reported by all providers to be challenging. Transport costs and poor access to the health facility were the main reasons for a patient failing to return to the clinic for a scheduled follow-up visit. Treatment was perceived to be safe by both providers and patients and reported no case of a severe adverse event. Some providers were concerned with the haemoglobin drop observed on day 7.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Single-low dose primaquine was perceived to be safe and acceptable among providers and patients. PROMPT demonstrated to be a reliable and user-friendly tool among providers. Further validation of the tool by involving the National Malaria Control Programme is pivotal to addressing key challenges and facilitating primaquine adoption in the national policy.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12936-021-03921-w","type":"journal-article","created":{"date-parts":[[2021,10,10]],"date-time":"2021-10-10T20:05:27Z","timestamp":1633896327000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Safety monitoring experience of single-low dose primaquine co-administered with artemether\u2013lumefantrine among providers and patients in routine healthcare practice: a qualitative study in Eastern Tanzania"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7258-9289","authenticated-orcid":false,"given":"Dominic","family":"Mosha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mwaka A.","family":"Kakolwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhidin K.","family":"Mahende","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honorati","family":"Masanja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salim","family":"Abdulla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Drakeley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Gosling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce","family":"Wamoyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,9]]},"reference":[{"key":"3921_CR1","volume-title":"World malaria report 2019","author":"WHO","year":"2020","unstructured":"WHO. World malaria report 2019. Geneva: World Health Organization; 2020."},{"key":"3921_CR2","volume-title":"Tanzania Malaria Indicator Survey 2017","author":"Ministry of Health Tanzania","year":"2018","unstructured":"Ministry of Health Tanzania, National Bureau of Statistics, ICF. Tanzania Malaria Indicator Survey 2017. Dar es Salaam: Ministry of Health Tanzania; 2018."},{"key":"3921_CR3","volume-title":"Malaria eradication: benefits, future scenarios and feasibility","author":"WHO","year":"2020","unstructured":"WHO. Malaria eradication: benefits, future scenarios and feasibility. Geneva: World Health Organization; 2020."},{"key":"3921_CR4","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1314981","volume":"371","author":"EA Ashley","year":"2014","unstructured":"Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S, et al. Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2014;371:411\u201323.","journal-title":"N Engl J Med"},{"key":"3921_CR5","doi-asserted-by":"publisher","first-page":"e37166","DOI":"10.1371\/journal.pone.0037166","volume":"7","author":"RJ Maude","year":"2012","unstructured":"Maude RJ, Socheat D, Nguon C, Saroth P, Dara P, Li G, et al. Optimising strategies for Plasmodium falciparum malaria elimination in Cambodia: primaquine, mass drug administration and artemisinin resistance. PLoS ONE. 2012;7:e37166.","journal-title":"PLoS ONE"},{"key":"3921_CR6","volume-title":"Policy brief on single-low dose primaquine as a gametocytocide in Plasmodium falciparum malaria","author":"WHO","year":"2015","unstructured":"WHO. Policy brief on single-low dose primaquine as a gametocytocide in Plasmodium falciparum malaria. Geneva: World Health Organization; 2015."},{"key":"3921_CR7","doi-asserted-by":"publisher","first-page":"e0190272","DOI":"10.1371\/journal.pone.0190272","volume":"13","author":"GJH Bastiaens","year":"2018","unstructured":"Bastiaens GJH, Tiono AB, Okebe J, Pett HE, Coulibaly SA, Goncalves BP, et al. Safety of single low-dose primaquine in glucose-6-phosphate dehydrogenase deficient falciparum-infected African males: two open-label, randomised, safety trials. PLoS ONE. 2018;13:e0190272.","journal-title":"PLoS ONE"},{"key":"3921_CR8","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1186\/s12879-019-3862-1","volume":"19","author":"L Dysoley","year":"2019","unstructured":"Dysoley L, Kim S, Lopes S, Khim N, Bjorges S, Top S, et al. The tolerability of single low dose primaquine in glucose-6-phosphate deficient and normal falciparum-infected Cambodians. BMC Infect Dis. 2019;19:250.","journal-title":"BMC Infect Dis"},{"key":"3921_CR9","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1186\/s12936-016-1341-3","volume":"15","author":"R Mwaiswelo","year":"2016","unstructured":"Mwaiswelo R, Ngasala BE, Jovel I, Gosling R, Premji Z, Poirot E, et al. Safety of a single low-dose of primaquine in addition to standard artemether-lumefantrine regimen for treatment of acute uncomplicated Plasmodium falciparum malaria in Tanzania. Malar J. 2016;15:316.","journal-title":"Malar J"},{"key":"3921_CR10","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/s12936-019-2841-8","volume":"18","author":"J Raman","year":"2019","unstructured":"Raman J, Allen E, Workman L, Mabuza A, Swanepoel H, Malatje G, et al. Safety and tolerability of single low-dose primaquine in a low-intensity transmission area in South Africa: an open-label, randomised controlled trial. Malar J. 2019;18:209.","journal-title":"Malar J"},{"key":"3921_CR11","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1186\/1475-2875-11-418","volume":"11","author":"NJ White","year":"2012","unstructured":"White NJ, Qiao LG, Qi G, Luzzatto L. Rationale for recommending a lower dose of primaquine as a Plasmodium falciparum gametocytocide in populations where G6PD deficiency is common. Malar J. 2012;11:418.","journal-title":"Malar J"},{"key":"3921_CR12","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/978-3-319-66242-8_12","volume":"71","author":"B Anaemene","year":"2018","unstructured":"Anaemene B. Health and diseases in Africa. Dev Afr. 2018;71:207\u201326.","journal-title":"Dev Afr"},{"key":"3921_CR13","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1186\/s12936-015-0714-3","volume":"14","author":"I Chen","year":"2015","unstructured":"Chen I, Poirot E, Newman M, Kandula D, Shah R, Hwang J, et al. An assessment of the supply, programmatic use, and regulatory issues of single low-dose primaquine as a Plasmodium falciparum gametocytocide for sub-Saharan Africa. Malar J. 2015;14:204.","journal-title":"Malar J"},{"key":"3921_CR14","unstructured":"MEI. Primaquine roll out monitoring pharmacovigilance tool. UCSF Global Health Group's Malaria Elimination Initiative 2015."},{"key":"3921_CR15","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1186\/s12936-016-1410-7","volume":"15","author":"E Poirot","year":"2016","unstructured":"Poirot E, Soble A, Ntshalintshali N, Mwandemele A, Mkhonta N, Malambe C, et al. Development of a pharmacovigilance safety monitoring tool for the rollout of single low-dose primaquine and artemether-lumefantrine to treat Plasmodium falciparum infections in Swaziland: a pilot study. Malar J. 2016;15:384.","journal-title":"Malar J"},{"key":"3921_CR16","doi-asserted-by":"publisher","first-page":"e1001339","DOI":"10.1371\/journal.pmed.1001339","volume":"9","author":"RE Howes","year":"2012","unstructured":"Howes RE, Piel FB, Patil AP, Nyangiri OA, Gething PW, Dewi M, et al. G6PD deficiency prevalence and estimates of affected populations in malaria endemic countries: a geostatistical model-based map. PLoS Med. 2012;9:e1001339.","journal-title":"PLoS Med"},{"key":"3921_CR17","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1186\/s12936-018-2446-7","volume":"17","author":"RA Khatib","year":"2018","unstructured":"Khatib RA, Chaki PP, Wang DQ, Mlacha YP, Mihayo MG, Gavana T, et al. Epidemiological characterisation of malaria in rural southern Tanzania following China\u2013Tanzania pilot joint malaria control baseline survey. Malar J. 2018;17:292.","journal-title":"Malar J"},{"key":"3921_CR18","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/S1473-3099(13)70268-8","volume":"14","author":"AC Eziefula","year":"2014","unstructured":"Eziefula AC, Bousema T, Yeung S, Kamya M, Owaraganise A, Gabagaya G, et al. Single dose primaquine for clearance of Plasmodium falciparum gametocytes in children with uncomplicated malaria in Uganda: a randomised, controlled, double-blind, dose-ranging trial. Lancet Infect Dis. 2014;14:130\u20139.","journal-title":"Lancet Infect Dis"},{"key":"3921_CR19","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1086\/499363","volume":"42","author":"CA Petti","year":"2006","unstructured":"Petti CA, Polage CR, Quinn TC, Allan RR, Merle AS. Laboratory medicine in Africa: a barrier to effective health care. Clin Infect Dis. 2006;42:377\u201382.","journal-title":"Clin Infect Dis"},{"key":"3921_CR20","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1136\/jcp.53.12.933","volume":"53","author":"CF Ingram","year":"2000","unstructured":"Ingram CF, Lewis SM. Clinical use of WHO haemoglobin colour scale: validation and critique. J Clin Pathol. 2000;53:933\u20137.","journal-title":"J Clin Pathol"},{"key":"3921_CR21","doi-asserted-by":"publisher","first-page":"e0006230","DOI":"10.1371\/journal.pntd.0006230","volume":"12","author":"J Recht","year":"2018","unstructured":"Recht J, Ashley EA, White NJ. Use of primaquine and glucose-6-phosphate dehydrogenase deficiency testing: divergent policies and practices in malaria endemic countries. PLoS Negl Trop Dis. 2018;12:e0006230.","journal-title":"PLoS Negl Trop Dis"},{"key":"3921_CR22","unstructured":"Ministry of Health, Community Development, Gender, Elderly and Children, National Bureau of Statistics, ICF. Tanzania demographic and health survey and malaria indicator survey (THDS-MIS) 2015\u201316. Dar es Salaam, Tanzania, 2016."},{"key":"3921_CR23","volume-title":"The role of RDTs in malaria control","author":"WHO","year":"2015","unstructured":"WHO. The role of RDTs in malaria control. Geneva: World Health Organization; 2015."},{"key":"3921_CR24","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.4081\/jphr.2018.1445","volume":"7","author":"E Osuna","year":"2018","unstructured":"Osuna E, Perez-Carrion A, Perez-Carceles MD, Machado F. Perceptions of health professionals about the quality of communication and deliberation with the patient and its impact on the health decision making process. J Public Health Res. 2018;7:1445.","journal-title":"J Public Health Res"},{"key":"3921_CR25","first-page":"S1-60-64","volume":"19","author":"S Naicker","year":"2009","unstructured":"Naicker S, Plange-Rhule J, Tutt RC, Eastwood JB. Shortage of healthcare workers in developing countries\u2013Africa. Ethn Dis. 2009;19:S1-60\u20134.","journal-title":"Ethn Dis"},{"key":"3921_CR26","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1093\/heapro\/15.4.369","volume":"15","author":"S Carlisle","year":"2000","unstructured":"Carlisle S. Health promotion, advocacy and health inequalities: a conceptual framework. Health Promot Int. 2000;15:369\u201376.","journal-title":"Health Promot Int"},{"key":"3921_CR27","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1186\/s12889-020-08926-9","volume":"20","author":"S Litzkendorf","year":"2020","unstructured":"Litzkendorf S, Frank M, Babac A, Rosenfeldt D, Schauer F, Hartz T, et al. Use and importance of different information sources among patients with rare diseases and their relatives over time: a qualitative study. BMC Public Health. 2020;20:860.","journal-title":"BMC Public Health"},{"key":"3921_CR28","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1177\/2374373517706611","volume":"4","author":"LK O'Brien","year":"2017","unstructured":"O\u2019Brien LK, Drobnick P, Gehman M, Hollenbeak C, Iantosca MR, Luchs S, et al. Improving responsiveness to patient phone calls: a pilot study. J Patient Exp. 2017;4:101\u20137.","journal-title":"J Patient Exp"},{"key":"3921_CR29","first-page":"23","volume":"153","author":"P Carayon","year":"2010","unstructured":"Carayon P, Wood KE. Patient safety\u2014the role of human factors and systems engineering. Stud Health Technol Inform. 2010;153:23\u201346.","journal-title":"Stud Health Technol Inform"},{"key":"3921_CR30","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/S1473-3099(11)70054-8","volume":"11","author":"DJ Morgan","year":"2011","unstructured":"Morgan DJ, Okeke IN, Laxminarayan R, Perencevich EN, Weisenberg S. Non-prescription antimicrobial use worldwide: a systematic review. Lancet Infect Dis. 2011;11:692\u2013701.","journal-title":"Lancet Infect Dis"},{"key":"3921_CR31","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s12889-019-6470-5","volume":"19","author":"S Tesfamariam","year":"2019","unstructured":"Tesfamariam S, Anand IS, Kaleab G, Berhane S, Woldai B, Habte E, et al. Self-medication with over the counter drugs, prevalence of risky practice and its associated factors in pharmacy outlets of Asmara, Eritrea. BMC Public Health. 2019;19:159.","journal-title":"BMC Public Health"},{"key":"3921_CR32","unstructured":"Sanofi. Fighting malaria factsheet. Sanofi 2020. https:\/\/www.sanofi.com\/-\/media\/Project\/One-Sanofi-Web\/Websites\/Global\/Sanofi-COM\/Home\/en\/our-responsibility\/docs\/documents-center\/factsheets\/Fighting-Malaria.pdf?la=en."},{"key":"3921_CR33","unstructured":"Crushing tablets or opening capsules: many uncertainties, some established dangers. Prescrire Int. 2014;23:209\u201311, 213\u20134"},{"key":"3921_CR34","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/j.ejca.2010.12.003","volume":"47","author":"ML Kimman","year":"2011","unstructured":"Kimman ML, Dirksen CD, Voogd AC, Falger P, Gijsen BC, et al. Nurse-led telephone follow-up and an educational group programme after breast cancer treatment: results of a 2 x 2 randomised controlled trial. Eur J Cancer. 2011;47:1027\u201336.","journal-title":"Eur J Cancer"},{"key":"3921_CR35","doi-asserted-by":"publisher","first-page":"e12730","DOI":"10.1111\/ecc.12730","volume":"27","author":"L Klaassen","year":"2018","unstructured":"Klaassen L, Dirksen C, Boersma L, Hoving C. Developing an aftercare decision aid; assessing health professionals\u2019 and patients\u2019 preferences. Eur J Cancer Care (Engl). 2018;27:e12730.","journal-title":"Eur J Cancer Care (Engl)."},{"key":"3921_CR36","first-page":"853","volume":"97","author":"M Maskew","year":"2007","unstructured":"Maskew M, MacPhail P, Menezes C, Rubel D. Lost to follow up: contributing factors and challenges in South African patients on antiretroviral therapy. S Afr Med J. 2007;97:853\u20137.","journal-title":"S Afr Med J"},{"key":"3921_CR37","doi-asserted-by":"publisher","first-page":"e40183","DOI":"10.1371\/journal.pone.0040183","volume":"7","author":"TN Nissen","year":"2012","unstructured":"Nissen TN, Rose MV, Kimaro G, Bygbjerg IC, Mfinanga SG, Ravn P. Challenges of loss to follow-up in tuberculosis research. PLoS ONE. 2012;7:e40183.","journal-title":"PLoS ONE"},{"key":"3921_CR38","unstructured":"Wyrzykowski R. Mobile connectivity in sub-Saharan Africa: 4G and 3G connections overtake 2G for the first time. GSMA. 2020. https:\/\/www.gsma.com\/mobilefordevelopment\/blog\/mobile-connectivity-in-sub-saharan-africa-4g-and-3g-connections-overtake-2g-for-the-first-time\/."},{"key":"3921_CR39","first-page":"13","volume":"1","author":"J Tabler","year":"2014","unstructured":"Tabler J, Scammon DL, Kim J, Farrell T, Tomoaia-Cotisel A, Magill MK. Patient care experiences and perceptions of the patient-provider relationship: a mixed method study. Patient Exp J. 2014;1:13.","journal-title":"Patient Exp J"},{"key":"3921_CR40","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1186\/s12936-018-2509-9","volume":"17","author":"NJ White","year":"2018","unstructured":"White NJ. Anaemia and malaria. Malar J. 2018;17:371.","journal-title":"Malar J"}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-021-03921-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12936-021-03921-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-021-03921-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T16:50:57Z","timestamp":1673455857000},"score":1,"resource":{"primary":{"URL":"https:\/\/malariajournal.biomedcentral.com\/articles\/10.1186\/s12936-021-03921-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,9]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["3921"],"URL":"https:\/\/doi.org\/10.1186\/s12936-021-03921-w","relation":{},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,9]]},"assertion":[{"value":"2 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was granted by the Ifakara Health Institute (IHI) ethical review board and the Tanzania National Research Ethics Committee (Number NIMR\/HQ\/R.8a\/Vol.IX\/3114). Assent and written informed consent were obtained from participants and their parents\/guardians, respectively.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participants"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"RG is leading the MEI at the University of California San Francisco, the institute that developed the PROMPT. MEI did not influence the results of the present study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"392"}}